Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst
D E
DE
1000 Veteran Avenue Rehabilitation Centre, Room 32-59, Los Angeles, CA 90024, USA. defurst@mednet.ucla.edu
Breedveld
F C
FC
Kalden
J R
JR
Smolen
J S
JS
Burmester
G R
GR
Bijlsma
J W J
JW
Dougados
M
M
Emery
P
P
Keystone
E C
EC
Klareskog
L
L
Mease
P J
PJ
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D019317:Evidence-Based Medicine; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012795:Sialoglycoproteins / Q000037:antagonists & inhibitors*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha